1. Home
  2. PLG vs IMUX Comparison

PLG vs IMUX Comparison

Compare PLG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.44

Market Cap

203.3M

Sector

N/A

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$16.47

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
IMUX
Founded
2000
2016
Country
Canada
United States
Employees
N/A
66
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.3M
209.2M
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
PLG
IMUX
Price
$1.44
$16.47
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
900.4K
133.5K
Earning Date
04-10-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$0.51
52 Week High
$4.04
$16.86

Technical Indicators

Market Signals
Indicator
PLG
IMUX
Relative Strength Index (RSI) 51.20 65.03
Support Level $1.24 $0.75
Resistance Level $1.61 N/A
Average True Range (ATR) 0.08 1.08
MACD 0.01 0.25
Stochastic Oscillator 52.05 88.54

Price Performance

Historical Comparison
PLG
IMUX

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: